Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline Delamanid and Linezolid) With the Current South African Standard of Care

of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) and clofazimine (CFZ) compared to the current South African Standard of Care (Control Strategy) for 9 months for

bedaquiline
ethambutol
linezolid
isoniazid
treatment regimen
  • 0 views
  • 16 Oct, 2021
  • 1 location
  • 0 views
  • 21 Sep, 2022
  • 40 locations
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)

study is to evaluate the potential effect of pretomanid on human testicular function whilst being used in a 26 weeks antimicrobial combination regimen consisting of bedaquiline (B) plus pretomanid (Pa

  • 2 views
  • 18 Oct, 2021
  • 2 locations
Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

This study is a randomized, controlled, multi-center clinical study. The main purpose of this study was to study the efficacy and safety data of total oral short-term therapy as an alternative to injection in the treatment of newly diagnosed RR-TB patients.

  • 4 views
  • 25 Jan, 2021
  • 1 location
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis (PandrTB)

PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations

bedaquiline
linezolid
moxifloxacin
delamanid
pyrazinamide
  • 5 views
  • 03 Mar, 2022
  • 4 locations
Bioneer Accupower Q-RFIA PCR Kit Clinical Evaluation

disease. The FQ are key components of the new bedaquiline-containing 6-9 month regimen, and so it is necessary to rule-out resistance to these compounds prior to treating patients with the shorter regimen

  • 0 views
  • 26 Apr, 2022
  • 1 location